Modality
Radioligand
MOA
SGLT2i
Target
MALT1
Pathway
Angiogenesis
NMOSD
Development Pipeline
Preclinical
~Apr 2013
→ ~Jul 2014
Phase 1
~Oct 2014
→ ~Jan 2016
Phase 2
~Apr 2016
→ ~Jul 2017
Phase 3
~Oct 2017
→ ~Jan 2019
NDA/BLA
Apr 2019
→ Aug 2026
NDA/BLACurrent
NCT06506281
281 pts·NMOSD
2019-04→2026-08·Terminated
281 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-08-165mo awayPh3 Readout· NMOSD
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2026-08-16 · 5mo away
NMOSD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06506281 | NDA/BLA | NMOSD | Terminated | 281 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 |